Skip to main content
. 2024 Sep 10;14:1428464. doi: 10.3389/fonc.2024.1428464

Table 3.

Recommendation plan for a vaccination strategy.

Pathogen Non-live
vaccines types		 MA Dose
series		 Time to start Duration
Revaccinate		 Sero
Conversion %
Before treatment* Anytime**
Pneumococcal PPSV23 IM/SC 1 Inline graphic                           Inline graphic every 5 y 0-100 (90)
Haemophilus
influenzae		 Hib IM 1 Inline graphic                           Inline graphic graphic file with name fonc-14-1428464-i009.jpg 48 (91)
Respiratory syncytial virus RSV IM 1 Inline graphic                           Inline graphic graphic file with name fonc-14-1428464-i009.jpg 41 (92)
Meningococcal MenACWY
MenB		 IM 2
2		 Inline graphic                           Inline graphic every 5 y No data
Influenza IIV4, ccIIV4, RIV4, aIIV4;
HD-IIV		 IM 1 Inline graphic                           Inline graphic every year 0-42 (90)
Herpes Zoster VZV IM/SC 2 Inline graphic                           Inline graphic graphic file with name fonc-14-1428464-i009.jpg 40-80 (90)
Sars Cov2 Covid19 IM 1 Inline graphic                           Inline graphic every year 18-60 (90)
Tetanus
Diphtheria		 Td IM 1 Inline graphic                           Inline graphic every 10 y No data

*Better before antiCD20 antibody therapy. Defer after 12 months from the end of chemoimmuno-therapy.

**Inline graphic During target therapies (BTKi or Bcl2i) prefer when disease is under control.

Inline graphic No Guidance/ No evidence.

MA mode administration: IM intramuscularly; SC subcutaneously.

See Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and Centers for Disease Control and Prevention (www.cdc.gov) and ASCO guideline (DOI https://doi.org/10.1200/JCO.24.00032).